Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

@article{Heiden2006EfficacyAT,
  title={Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia.},
  author={Pim L. J. van der Heiden and Inge Jedema and Roel Willemze and Renee M. Y. Barge},
  journal={European journal of haematology},
  year={2006},
  volume={76 5},
  pages={409-13}
}
Gemtuzumab ozogamicin (GO) is a recently developed antibody-targeted chemotherapeutic agent and has been expected to be less toxic than conventional chemotherapy. We retrospectively evaluated the use of GO in 38 patients. Patients with acute myeloid leukemia (AML) at diagnosis and relapsed AML were treated with 6 and 9 mg/m(2) GO. Efficacy and toxicity of GO were analyzed, as well as several prognostic factors. A complete response (CR) was observed in 12 of 38 patients, including five patients… CONTINUE READING